David E. Gerber

The paper identifies DPP9 as a genetic susceptibility gene for checkpoint inhibitor pneumonitis and shows IL-18 blockade could be a therapeutic strategy.

This paper develops a novel MICA/B-targeting antibody that enhances NK cell activity and shows therapeutic efficacy in KRAS LKB1 mutant lung cancer models.

The paper compares systemic immune parameters between Black and White lung cancer patients, finding significant differences in cytokine levels and immune cell populations.

Cmai predicts antigen-antibody interactions from high-throughput BCR sequencing data, revealing immune responses to tumor antigens and ICI treatment outcomes.

This paper develops pMTnet-omni, an AI system predicting TCR-pMHC binding across species and MHC classes, achieving high accuracy and showing clinical utility in predicting immune-related adverse events.